nano-GLA
administered GLA
Nanoformulated GLA
final GLA nanoformulation
Smart multifunctional GLA-nanoformulation
new liposomal nanoformulation of GLA
Fabry project
tailored transport of GLA
treatment of Fabry disease
free GLA recombinant protein
case of Fabry LSD Disease
Fabry disease Lysosomal storage disorders
novel nanoformulation
Fulfillment of Smart
FD
cell membranes
group of rare diseases
BBB
LSD incidence
KETs
ERT
manufacturing
major health problem
low efficacy
higher efficacy
serious global health problem
current treatment
important impact
existence of new therapies
enzyme activity results
Enzyme Replacement Therapy
PD profile
kidneys
assembly
different molecular components
TRL3
cellular accumulation of neutral glycosphingolipids
widespread vasculopathy
cross biological barriers
experimental PoC
heart
preclinical regulatory phase
particular detriment
nanotechnology
industrial biotechnology
instability
excellent quality control
better PK
Î±-Galactosidase
aim of Samrt
advanced materials
contribution
high immunogenicity
priority societal challenge
deficiency
use of green cCO2
H2020 Work Programmes
nervous system
TRL5
European Strategy
GMPs
one-step method
definitive cure
patients
growth
drawbacks
jobs
decline